GENZYME CORP Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost

GENZYME CORP Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost

GENZYME CORP had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $173.36 million as of 2010-12-31, per its 10-K filed 2011-03-01.

Discontinued › Notes › Income Taxes › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense

us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2011-03-01

• 2010-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $173.36M.
• 2009-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $183.40M.